Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

European Urology

Volumn 68, Issue 2, 2015, Pages 317-324

  Brasso, Klaus ^a   Thomsen, Frederik B ^a   Schrader, Andres J ^b   Schmid, Sebastian C ^c   Lorente, David ^d   Retz, Margitta ^c   Merseburger, Axel S ^e   Von Klot, Christoph A ^e   Boegemann, Martin ^f   De Bono, Johann ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Abiraterone; Castration resistant prostate cancer; Docetaxel; Enzalutamide; PSA; Survival

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPASSIONATE USE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; DRUG SUBSTITUTION; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; EUROPE; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937526237     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.07.028     Document Type: Article

References (24)

1. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. D.P. Petrylak, C.M. Tangen, M.H.A. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. J.S. De Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. P.W. Kantoff, C.S. Higano, N.D. Shore, and et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
5. J.S. De Bono, C.J. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
7. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
8. T.M. Beer, A.J. Armstrong, C.N. Sternberg, and et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study [abstract] J Clin Oncol 32 Suppl 4 2014
9. J.E. Ang, D. Olmos, and J.S. de Bono CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer Br J Cancer 100 2009 671 675
10. C. Tran, S. Ouk, N.J. Clegg, and et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
11. K. Fizazi, H.I. Scher, A. Molina, and et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
12. Y. Loriot, D. Bianchini, E. Ileana, and et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
13. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
14. A.J. Schrader, M. Boegemann, C.-H. Ohlmann, and et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
15. S.C. Schmid, A. Geith, A. Böker, and et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer Adv Ther 31 2014 234 241
16. D. Bianchini, D. Lorente, A. Rodriguez-Vida, and et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
17. F.B. Thomsen, M.A. Røder, P. Rathenborg, K. Brasso, M. Borre, and P. Iversen Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scand J Urol 48 2014 268 275
18. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. J.A. Schalken Molecular aspects of hormone-independent prostate cancer BJU Int 100 Suppl 2 2007 52 55
20. R.J. Van Soest, M.E. van Royen, E.S. de Morrée, and et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer 49 2013 3821 3830
21. M.-L. Zhu, C.M. Horbinski, M. Garzotto, D.Z. Qian, T.M. Beer, and N. Kyprianou Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002
22. M. Thadani-Mulero, D.M. Nanus, and P. Giannakakou Androgen receptor on the move: boarding the microtubule expressway to the nucleus Cancer Res 72 2012 4611 4615
23. V.K. Arora, E. Schenkein, R. Murali, and et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
24. J. Mezynski, C. Pezaro, D. Bianchini, and et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947